Form 4: Krystal Biotech Director Julian S. Gangolli Executes Stock Option and Sells Shares

Director Julian S. Gangolli exercised stock options and sold shares of Krystal Biotech (KRYS) on May 20, 2024.

Summary

• On May 20, 2024, Julian S. Gangolli, a director of Krystal Biotech, Inc. (KRYS), exercised stock options to acquire 20,000 shares of common stock at a price of $22.75 per share.
• Simultaneously, Gangolli sold a total of 20,000 shares of common stock in multiple transactions.
• The sales were executed at weighted average prices ranging from $163.7063 to $165.7576.
• Following these transactions, Gangolli's direct ownership of Krystal Biotech common stock is reported as 0 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• Shareholders may interpret the director's stock sale in various ways, potentially affecting investor sentiment.

Key Dates